Edition:
India

Sientra Inc (SIEN.OQ)

SIEN.OQ on NASDAQ Stock Exchange Global Select Market

11.00USD
2:29am IST
Change (% chg)

$-0.65 (-5.58%)
Prev Close
$11.65
Open
$11.57
Day's High
$11.66
Day's Low
$10.51
Volume
146,683
Avg. Vol
46,683
52-wk High
$16.61
52-wk Low
$7.21

Chart for

About

Sientra, Inc. is a medical aesthetics company. The Company's primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast... (more)

Overall

Beta: --
Market Cap(Mil.): $307.56
Shares Outstanding(Mil.): 19.31
Dividend: --
Yield (%): --

Financials

BRIEF-Sientra Announces Preliminary Unaudited Q4 Revenue

* SIENTRA ANNOUNCES PRELIMINARY UNAUDITED FOURTH QUARTER 2017 REVENUE

08 Jan 2018

BRIEF-Sientra Inc Files For Mixed Shelf Of Upto $150 Million

* SIENTRA INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING Source text (http://bit.ly/2ADjKzY) Further company coverage:

08 Jan 2018

BRIEF-Sientra posts qtrly loss of $0.74​ per share

* Total net sales for Q3 2017 were $9.8 million, compared to total net sales of $6.5 million for same period in 2016​

08 Nov 2017

BRIEF-Sientra's ‍total net sales for Q3 2017 were $9.8 million

* Sientra - ‍total net sales for Q3 2017 were $9.8 million, compared to $6.5 million for same period in 2016

08 Nov 2017

BRIEF-Sientra reports Q2 net loss per share attributable to stockholders $1.07​

* Sientra Inc qtrly ‍basic and diluted net loss per share attributable to common stockholders $1.07​ Source text for Eikon: Further company coverage:

10 Aug 2017

BRIEF-Sientra, Silimed reach settlement of lawsuit and related arbitration

* Sientra says on June 27, co, Silimed Ind*A De Implantes Ltda reached settlement of lawsuit and related arbitration between them - SEC filing

01 Aug 2017

Competitors

  Price Chg
Allergan plc (AGN.N) $178.66 +2.61
Johnson & Johnson (JNJ.N) $146.86 +1.10

Earnings vs. Estimates